APVO603 / Aptevo Therap - LARVOL DELTA

Aptevo Highlights APVO603: A Novel Bispecific Antibody Targeting 4-1BB and OX40 for Enhanced Solid Tumor Immunotherapy (ACCESSWIRE) - "Aptevo Therapeutics...provided an overview of solid tumor anti-cancer compound APVO603, currently in preclinical development for the treatment of solid tumors....APVO603 is designed to activate the costimulatory 4-1BB and OX40 pathways in the tumor microenvironment, leading to enhanced T cell expansion, survival, and cytotoxic function while avoiding systemic toxicity....Preclinical studies have shown that APVO603: Enhances T cell and NK cell proliferation and tumor lysis, while maintaining a favorable safety profile and inhibiting immune exhaustion; Induces a robust anti-tumor response in preclinical tumor models, suggesting strong therapeutic potential."

Preclinical • Solid Tumor

APVO603: A dual 4-1BB and OX40 bispecific approach utilizing ADAPTIRTM technology designed to deliver a conditional T cell/NK response against solid tumors (SITC 2021) - "Further, mechanistic evaluation supports the ability of APVO603 to pair with T-cell modulating IO approaches to support a more fit T cell response and favorable TME. This preclinical data supports further development of APVO603, a promising immuno-oncology therapeutic with potential for benefit in hematologic and solid tumors."

IO biomarker • Oncology • Solid Tumor • CD4 • CD8 • TNFRSF4 • TNFRSF9

Aptevo Therapeutics Reports Third Quarter Financial Results With Business Highlights (Yahoo Finance) - "Business Highlights: Showcased the Company's preclinical assets, APVO442 and APVO603, and their potential to improve efficacy in the treatment of solid tumors and participated in discussions about risk mitigation in cell engager candidates at the Virtual Cell Engager Summit."

Preclinical • Oncology • Solid Tumor

Aptevo Therapeutics Announces Preclinical Data for Bispecific Antibody APVO603 at the Society for Immunology in Cancer Annual Meeting (Yahoo Finance) - "Aptevo Therapeutics...announced the presentation of preclinical data for APVO603, the Company's bispecific antibody targeting 4-1BB (CD137) and OX40 (CD134), at the Society for Immunology in Cancers (SITC) 2021 Annual Meeting....Data in the poster showed that APVO603 enhanced dose-dependent control of in vitro tumor cell lysis when paired with a bispecific T-cell engager when compared either alone. Of note, investigators show that APVO603 has minimal impact on regulatory T cell suppression of CD8+ T cells' proliferation in vitro."

Preclinical • Oncology

[VIRTUAL] APVO603: A dual 4-1BB and OX40 bispecific approach utilizing ADAPTIRTMtechnology designed to deliver a conditional T cell/NK response against solid tumors (AACR 2021) - "This preclinical data demonstrates conditional dual stimulation of 4-1BB and OX40 and supports further development of APVO603, a promising immuno-oncology therapeutic with potential for benefit in solid tumors. This program is progressing into IND-enabling studies later this year."

IO biomarker • Late-breaking abstract • Bladder Cancer • Oncology • Solid Tumor • Urothelial Cancer • CD4 • CD8 • GZMB

Aptevo Therapeutics to Present at the American Association for Cancer Research Virtual Annual Meeting (Yahoo Finance) - "Aptevo Therapeutics...announced that it will present two new posters at the American Association for Cancer Research Virtual Annual Meeting, to be held in two virtual sessions - Saturday, April 10th to Thursday, April 15th, 2021 and Monday, May 17th to Friday, May 21st, 2021. The posters will provide preclinical updates on APVO603 and Aptevo's newest pipeline candidate, APVO442."

Preclinical • Oncology • Solid Tumor

[VIRTUAL] Dual-targeting of 4-1BB and OX40 with an ADAPTIR™ bispecific antibody enhances anti-tumor responses to solid tumor (SITC 2020) - "Conclusions APVO603 is a dual-agonistic bispecific antibody that augments the effector function of activated CD4+ and CD8+ T and NK cells in a dose-dependent manner, and reduces growth of established tumors in vivo. This preclinical data, demonstrates conditional dual stimulation of 4-1BB and OX40 and supports further development of APVO603, a promising immuno-oncology therapeutic with potential for benefit in solid tumors."

IO Biomarker • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • Urothelial Cancer • CD8 • GZMB • TNFRSF4

[VIRTUAL] Dual-targeting of 4-1BB and OX40 with an ADAPTIR™ bispecific antibody enhances anti-tumor responses to solid tumor (SITC 2020) - "Conclusions APVO603 is a dual-agonistic bispecific antibody that augments the effector function of activated CD4+ and CD8+ T and NK cells in a dose-dependent manner, and reduces growth of established tumors in vivo. This preclinical data, demonstrates conditional dual stimulation of 4-1BB and OX40 and supports further development of APVO603, a promising immuno-oncology therapeutic with potential for benefit in solid tumors."

IO Biomarker • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • Urothelial Cancer • CD8 • GZMB • TNFRSF4